Exelixis ($EXEL) reported a wider than expected lo
Post# of 64137
Posted On: 11/11/2015 9:09:55 AM
Exelixis ($EXEL) reported a wider than expected loss for its third quarter, while its revenues beat estimates. Separately, the company announced that the FDA has approved its treatment candidate COTELLIC it is co-promoting with Roche’s Genentech unit in combination with Vemurafenib for treating metastatic melanoma.
(0)
(0)Scroll down for more posts ▼